SIGRID’s Glucose Stabiliser Demonstrates Clinical Efficacy and U.S. Commercial Momentum Amid Growing Demand for Metabolic Health Solutions

Stockholm, Sweden – June 9, 2025. SIGRID, the Swedish healthtech innovator behind the patented SiPore® mineral technology, today announced new clinical and commercial milestones for its flagship product, Glucose Stabiliser. A recently completed clinical trial involving continuous tracking of glucose levels, alongside a real-world consumer experience study, demonstrates the product’s strong potential to support blood sugar regulation and appetite control, while avoidingmetabolic discomfort.

U.S. commercial results point to rapid, profitable scaling of Glucose Stabiliser.

Clinical Trial Confirms Glucose Control Benefits in Healthy Adults

In a 14-day, placebo-controlled, single-blind, crossover clinical study, 20 healthy adults (aged 18–64) completed two phases: 7 days without Glucose Stabiliser (placebo) and 7 days with Glucose Stabiliser, while wearing continuous glucose monitors (CGMs) and maintaining normal diets.

Key findings:

• Participants maintained an optimal glucose level for significantly longerduring the Glucose Stabiliser phase (p = 0.01 vs. placebo)

• Hypoglycemic events were reduced by an average of 85% compared to placebo, indicating enhanced metabolic stability (p = 0.004)

“What’s remarkable about this study is how definitively the data confirms our mode of action - meal by meal. Participants experienced a dramatic improvement when switching from placebo to Glucose Stabiliser, remaining in the optimalglucose range for almost 100% of the time. The impact is immediately visible andaligns perfectly with what our users report: a near-instant feeling of balance and control. This is science they can feel and measure,” commented Sana Alajmovic, Co-founder & CEO, SIGRID.

Consumer Experience Study Reinforces Real-World Benefits

A U.S. consumer experience study involving 152 customers showed similarly strong results, with users reporting early-onset improvements across multiple digestion- and satiety-related parameters:

• 93% felt fuller for longer after meals

• 89% noticed a reduced urge to snack

• 92% of users with bloating reported relief

These results underscore Glucose Stabiliser’s role in appetite regulation, metabolic comfort, and perceived glycemic stability. 

Commercial Breakthrough in the U.S.

SIGRID’s strong clinical and consumer insights are translating directly into commercial success. In May, the company achieved its fifth consecutive month of growth in the U.S., with standout metrics:

• +41% net sales growth from April

• 18% growth in New Customer Net Sales

• 68% net margin, driven by higher recurring revenue from updated subscription terms

• 4% reduction in customer acquisition cost (CAC)

Performance on Meta’s platforms has also improved substantially.

“These results demonstrate that we’re not only delivering clinically validated benefits but also engaging effectively in a high-demand market,” continues Sana Alajmovic. “SIGRID is well-positioned for rapid, profitable scaling.”

About Glucose Stabiliser and SiPore®

Glucose Stabiliser is powered by SiPore®, a patented food-grade mineral developed over 15 years of research in Sweden. It acts locally in the gut to trap digestive enzymes, slow the breakdown of carbs and fats, and reduce the rate of glucose absorption - supporting stable energy, appetite control, and fewer post-meal crashes. The SiPore® technology has been extensively studied in several clinical studies and published in multiple peer-reviewed publications. 

Partner With Us

With clinical evidence, real-world validation, and strong U.S. commercial momentum, SIGRID is in active dialogues with strategic partners and investors to expand its global footprint.

Media & Partnership Inquiries:
Sana Alajmovic
Co-founder & CEO 
SIGRID
sana@sigridthx.com
+46 723 893 396